Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

50.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,405
Open 50.41
Bid (Size) 59.25 (3)
Ask (Size) 59.45 (5)
Prev. Close 50.41
Today's Range 50.41 - 50.41
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace

Performance

YTD
+175.77%
+175.77%
1 Month
-3.28%
-3.28%
3 Month
-22.53%
-22.53%
6 Month
+135.01%
+135.01%
1 Year
+247.90%
+247.90%

More News

Read More
Nvidia, Ford, Chipotle, Viking Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,600 Today
Via Benzinga
Smart Money Is Betting Big In VKTX Options
Via Benzinga
Viking Therapeutics Stock Climbs On Q2 EPS Beat
Via Benzinga
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
Via Investor's Business Daily
3 Undervalued Biotech Stocks With Breakout Potential
Via InvestorPlace
Is Viking Therapeutics a Millionaire-Maker?
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
Via InvestorPlace
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Via Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Via Benzinga
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
Via Investor's Business Daily
Is Viking Therapeutics the Best Biotech Stock for You?
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
Via InvestorPlace
Is Viking Therapeutics Stock Running Out of Steam?
Via The Motley Fool
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Via The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
Via The Motley Fool
3 Overlooked Giants-in-the-Making for Patient Investors
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.